We discuss the challenges in treatment selection due to the patient’s compound de novo EGFR mutations, management of her osimertinib-induced hepatitis, and the successful re-introduction of osimertinib following the failure of alternative therapies. This evidence concerns the gene EGFR and hepatitis A virus infection.